Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Stock Sees RS Rating Jump To 93

ACADIA Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

ACADIA Pharmaceuticals Earns Relative Strength Rating Upgrade

ACADIA Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

ACADIA Pharmaceuticals Earns RS Rating Upgrade

A Relative Strength Rating upgrade for ACADIA Pharmaceuticals shows improving technical performance. Will it continue?

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

ACADIA Pharmaceuticals Shows Rising Price Performance With Jump To 82 RS Rating

A Relative Strength Rating upgrade for ACADIA Pharmaceuticals shows improving technical performance.

Investors Business Daily

ACADIA Pharmaceuticals Trying To Close In On Key Technical Measure

ACADIA Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'

Acadia Pharmaceuticals led a biotech stock sell-off Wednesday after revenue from its Rett syndrome treatment missed expectations.

Investors Business Daily

‘We have hope for some breakthroughs’: can we change the way we treat schizophrenia?

Scientists are cautiously optimistic that new approaches to treating the disabling condition may improve the lives of those affected by it

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022

Upgrades

Benzinga

Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis

HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc&#

Benzinga

Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 2.5% on Tuesday.

Benzinga

Acadia Pharmaceuticals Crashes After FDA Panel Votes Down Its Alzheimer's Psychosis Drug

FDA experts voted against Acadia Pharmaceuticals' Alzheimer's disease psychosis drug, leading ACAD stock to plummet.

Investors Business Daily

HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate

HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected.

Benzinga

Why Acadia Pharma Surged Despite A Negative FDA Take On Its Lead Drug

There were no surprises in the FDA's assessment of an Alzheimer's drug from Acadia Pharmaceuticals, and ACAD stock surged Wednesday.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

ACADIA Pharmaceuticals's Return On Capital Employed Insights

ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $115.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 162.35%, resulting in a loss of $113.06 million.

Benzinga

ACADIA Pharmaceuticals: Q1 Earnings Insights

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Benzinga

ACADIA Pharmaceuticals's Earnings Outlook

ACADIA Pharmaceuticals (NASDAQ:ACAD) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that ACADIA Pharmaceuticals will report an earnings per share (EPS) of $-0.60.

Benzinga

What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter:

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating

Acadia Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Benzinga

Expert Ratings For ACADIA Pharmaceuticals

Over the past 3 months, 18 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

ACADIA Pharmaceuticals's Return On Capital Employed Overview

ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $130.76 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 198.08%, resulting in a loss of $43.09 million.

Benzinga

Recap: ACADIA Pharmaceuticals Q4 Earnings

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Benzinga

Expert Ratings For ACADIA Pharmaceuticals

ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter:

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.